Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | UBE2N | P61088 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CASR | P41180 | 5/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12438855 | 0.84 | UBE2N (0.47) | L3MBTL1MAPTUBE2NCASRNOTUM | |
| SCHEMBL26970951 | 0.82 | GAA (0.49) | KDM4EL3MBTL1MAPTALDH1A1HPGD | |
| SCHEMBL9682529 | 0.82 | ALDH1A1 (0.67) | KDM4EL3MBTL1MAPTALDH1A1HPGD | |
| SCHEMBL2360605 | 0.82 | UBE2N (0.48) | MAPTALDH1A1UBE2NPOLBKMT2A | |
| SCHEMBL12514186 | 0.81 | MLYCD (0.43) | KDM4EL3MBTL1MAPTALDH1A1UBE2N | |
| SCHEMBL16322812 | 0.81 | MAPT (0.54) | KDM4EL3MBTL1MAPTALDH1A1HPGD | |
| SCHEMBL13832650 | 0.80 | GAA (0.66) | KDM4EL3MBTL1MAPTALDH1A1POLB | |
| SCHEMBL12438854 | 0.80 | UBE2N (0.44) | MAPTUBE2NCASRNOTUMNPC1 | |
| SCHEMBL28103504 | 0.79 | UBE2N (0.47) | KDM4EL3MBTL1MAPTALDH1A1UBE2N | |
| SCHEMBL5904691 | 0.79 | NOTUM (0.66) | CFTRNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722208-A1 | NOVEL BENZAMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Samjin Pharmaceutical Co., Ltd. (KR) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024246764-A1 | NOVEL BENZAMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 삼진제약주식회사 | 2024-12-05 | — | — | WO | disclosed |
| EP-2212284-B1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC (US) | 2014-04-30 | — | — | EP | disclosed |
| EP-2212284-B1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC (US) | 2014-04-30 | — | — | EP | disclosed |
| US-8334317-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334317-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-20110178133-A1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. | 2011-07-21 | — | — | US | disclosed |
| US-20110178133-A1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. | 2011-07-21 | — | — | US | disclosed |
| WO-2009051718-A2 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. (US) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178133-A1 | CALCIUM RECEPTOR MODULATING AGENTS | CASR, CALCR, RYR1 | KDM4E 4376/4885L3MBTL1 4865/4885MAPT 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.